ondansetron has been researched along with Female Genital Neoplasms in 11 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Successful control of vomiting was achieved in the first 24 hours, in 74% of the cycles containing cisplatin and 82% of the cycles without cisplatin, if ondansetron was used." | 9.08 | Ondansetron in chemotherapy-induced emesis. Our experience. ( Bandiera, AF; Fiorelli, C; Framarino dei Malatesta, M; Marzetti, L; Toccaceli Blasi, MR; Veneziano, M; Yacoub, M, 1995) |
| "Twenty-nine patients with gynecologic malignancies were treated with a fixed low dose of intravenous ondansetron (8 mg) plus dexamethasone (20 mg) in an effort to develop an effective and less expensive antiemetic regimen for the control of carboplatin-induced emesis." | 9.08 | Low-dose intravenous ondansetron (8 mg) plus dexamethasone: an effective regimen for the control of carboplatin-induced emesis. ( Belinson, J; Kennedy, A; Kulp, B; Markman, M; Peterson, G; Webster, K, 1997) |
| "The inhibitory effects of GG032X tablets, a new dosage form (fast dispersing tablet) of ondansetron, 5-HT2 receptor antagonist, on nausea and emesis induced by cisplatin (CDDP), were investigated along with safety and usefulness." | 9.08 | [Clinical efficacy of GG032X tablets, a new dosage form of ondansetron (fast dispersing tablet), on cisplatin-induced nausea and emesis]. ( Akasaka, Y; Ariyoshi, Y; Ikeda, M; Nukariya, N; Ota, J; Suminaga, M; Taguchi, T, 1997) |
| "To compare the efficacy between acupuncture and ondansetron in the prevention of delayed chemotherapy induced nausea and vomiting (CINV)." | 5.20 | Efficacy of acupuncture in prevention of delayed chemotherapy induced nausea and vomiting in gynecologic cancer patients. ( Akkayagorn, L; Manchana, T; Rithirangsriroj, K, 2015) |
| "To evaluate the antiemetic effect of a single dose of ondansetron and dexamethasone as a prophylaxis for chemotherapy induced acute nausea and emesis and factors associated with the control of acute nausea and emesis." | 5.12 | Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy. ( Manusirivithaya, S; Pradermdee, P; Sukwattana, P; Tangjitgamol, S; Thavaramara, T, 2006) |
| "The efficacy of an intravenous 5-HT3 antagonist (granisetron) and four oral 5-HT3 antagonists (granisetron, ondansetron, tropisetron and ramosetron) on chemotherapy-induced emesis were investigated in 21 gynecologic cancer patients (63 courses)." | 5.09 | [Effects of oral 5-HT3 antagonists on chemotherapy-induced emesis in patients with gynecologic cancers]. ( Akutagawa, N; Ishioka, S; Ito, E; Kiya, T; Kudo, R; Sagae, S; Saito, T; Sugimura, M; Umemura, K, 2000) |
| "The purpose of this study was to develop a cost-effective prophylactic antiemetic regimen for the prevention of carboplatin-induced emesis." | 5.09 | The antiemetic efficacy of oral ondansetron plus intravenous dexamethasone in patients with gynecologic malignancies receiving carboplatin-based chemotherapy. ( Belinson, J; Kennedy, A; Kulp, B; Markman, M; Peterson, G; Webster, K, 2000) |
| "Successful control of vomiting was achieved in the first 24 hours, in 74% of the cycles containing cisplatin and 82% of the cycles without cisplatin, if ondansetron was used." | 5.08 | Ondansetron in chemotherapy-induced emesis. Our experience. ( Bandiera, AF; Fiorelli, C; Framarino dei Malatesta, M; Marzetti, L; Toccaceli Blasi, MR; Veneziano, M; Yacoub, M, 1995) |
| "Twenty-nine patients with gynecologic malignancies were treated with a fixed low dose of intravenous ondansetron (8 mg) plus dexamethasone (20 mg) in an effort to develop an effective and less expensive antiemetic regimen for the control of carboplatin-induced emesis." | 5.08 | Low-dose intravenous ondansetron (8 mg) plus dexamethasone: an effective regimen for the control of carboplatin-induced emesis. ( Belinson, J; Kennedy, A; Kulp, B; Markman, M; Peterson, G; Webster, K, 1997) |
| "The inhibitory effects of GG032X tablets, a new dosage form (fast dispersing tablet) of ondansetron, 5-HT2 receptor antagonist, on nausea and emesis induced by cisplatin (CDDP), were investigated along with safety and usefulness." | 5.08 | [Clinical efficacy of GG032X tablets, a new dosage form of ondansetron (fast dispersing tablet), on cisplatin-induced nausea and emesis]. ( Akasaka, Y; Ariyoshi, Y; Ikeda, M; Nukariya, N; Ota, J; Suminaga, M; Taguchi, T, 1997) |
| "In the large majority of patients, serotonin-receptor antagonist antiemetic therapy, administered in combination with dexamethasone, is highly effective over multiple courses in preventing significant carboplatin-induced nausea and vomiting." | 3.71 | Effectiveness of serotonin-receptor antagonist antiemetic therapy over successive courses of carboplatin-based chemotherapy. ( Kulp, B; Markman, M; Markman, MR; Peterson, G, 2002) |
| " Adverse reactions were observed in 2 cases (2 reports of headache) in the OND group and 5 cases (2 reports of hiccups, 2 headache, 2 diarrhea, one constipation, one hot facial flushes and one elevation of gamma-GTP) in the DEX group; however, since the symptoms were all mild, we did not consider there was any problem in safety." | 2.70 | [Examination on efficacy and safety of concurrent use of ondansetron hydrochloride and steroid in gynecological cancer patients on cisplatin]. ( Eguchi, F; Furue, H; Ikeda, M; Taguchi, T; Tsukakoshi, S, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (36.36) | 18.2507 |
| 2000's | 6 (54.55) | 29.6817 |
| 2010's | 1 (9.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rithirangsriroj, K | 1 |
| Manchana, T | 1 |
| Akkayagorn, L | 1 |
| Pradermdee, P | 1 |
| Manusirivithaya, S | 1 |
| Tangjitgamol, S | 1 |
| Thavaramara, T | 1 |
| Sukwattana, P | 1 |
| Framarino dei Malatesta, M | 2 |
| Veneziano, M | 2 |
| Fiorelli, C | 2 |
| Bandiera, AF | 2 |
| Yacoub, M | 1 |
| Toccaceli Blasi, MR | 1 |
| Marzetti, L | 1 |
| Galati, M | 1 |
| Paolucci, A | 1 |
| Markman, M | 3 |
| Kennedy, A | 2 |
| Webster, K | 2 |
| Peterson, G | 3 |
| Kulp, B | 3 |
| Belinson, J | 2 |
| Ariyoshi, Y | 1 |
| Nukariya, N | 1 |
| Akasaka, Y | 1 |
| Suminaga, M | 1 |
| Ota, J | 1 |
| Ikeda, M | 2 |
| Taguchi, T | 2 |
| Ishioka, S | 1 |
| Sagae, S | 1 |
| Saito, T | 1 |
| Kiya, T | 1 |
| Sugimura, M | 1 |
| Akutagawa, N | 1 |
| Umemura, K | 1 |
| Ito, E | 1 |
| Kudo, R | 1 |
| Eguchi, F | 1 |
| Furue, H | 1 |
| Tsukakoshi, S | 1 |
| Markman, MR | 1 |
| Lehoczky, O | 1 |
| Udvary, J | 1 |
| Pulay, T | 1 |
9 trials available for ondansetron and Female Genital Neoplasms
| Article | Year |
|---|---|
Efficacy of acupuncture in prevention of delayed chemotherapy induced nausea and vomiting in gynecologic cancer patients.
Topics: Acupuncture Therapy; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cross | 2015 |
Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
Topics: Acute Disease; Adult; Age Factors; Anti-Inflammatory Agents; Antiemetics; Antineoplastic Agents; Cis | 2006 |
Ondansetron in chemotherapy-induced emesis. Our experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Female; Genital Neoplas | 1995 |
Low-dose intravenous ondansetron (8 mg) plus dexamethasone: an effective regimen for the control of carboplatin-induced emesis.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Carboplatin; Dexamethasone; Drug | 1997 |
[Clinical efficacy of GG032X tablets, a new dosage form of ondansetron (fast dispersing tablet), on cisplatin-induced nausea and emesis].
Topics: Administration, Oral; Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Drug Administratio | 1997 |
[Effects of oral 5-HT3 antagonists on chemotherapy-induced emesis in patients with gynecologic cancers].
Topics: Administration, Oral; Antiemetics; Benzimidazoles; Carboplatin; Cisplatin; Cyclophosphamide; Doxorub | 2000 |
The antiemetic efficacy of oral ondansetron plus intravenous dexamethasone in patients with gynecologic malignancies receiving carboplatin-based chemotherapy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Antineopla | 2000 |
[Examination on efficacy and safety of concurrent use of ondansetron hydrochloride and steroid in gynecological cancer patients on cisplatin].
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Drug Therapy, Combination; Female; Gen | 2001 |
Freeze dried ondansetron: first observations with the fast dissolving oral antiemetic Zofran Zydis for the prophylaxis of the cisplatin-induced emesis in gynecological cancer patients.
Topics: Administration, Oral; Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Female; Freeze D | 2002 |
2 other studies available for ondansetron and Female Genital Neoplasms
| Article | Year |
|---|---|
Ondansetron-induced headache. Our experience in gynecological cancer.
Topics: Breast Neoplasms; Female; Genital Neoplasms, Female; Headache; Humans; Migraine Disorders; Ondansetr | 1995 |
Effectiveness of serotonin-receptor antagonist antiemetic therapy over successive courses of carboplatin-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bridged | 2002 |